Benchmark lowered the firm’s price target on OmniAb (OABI) to $6 from $8 and keeps a Buy rating on the shares. Financial results for Q4 came in below the firm’s expectations, notes the analyst, who adds that “on the positive side,” OmniAb reported the signing of 10 new license agreements in 2024, including two in Q4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OABI: